Wilbanks Smith & Thomas Asset Management’s Revolution Medicines RVMD Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-9,041	Closed	-$249K	–	520
2021 Q3	$249K	Hold	9,041	–	–	0.01%	434
2021 Q2	$287K	Hold	9,041	–	–	0.01%	404
2021 Q1	$415K	Hold	9,041	–	–	0.02%	316
2020 Q4	$358K	Buy	+9,041	New	+$357K	0.02%	305

Other funds holding RVMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's RVMD Position: Q4 2021 in Review

Wilbanks Smith & Thomas Asset Management sold out of Revolution Medicines (RVMD) in Q4 2021, closing a stake of 9,041 shares — an estimated $249K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in RVMD in Q4 2020 and held it in 4 quarters. The position peaked at $415K in Q1 2021. 117 funds tracked by Wall St. Rank hold RVMD as of Q4 2021.

Wilbanks Smith & Thomas Asset Management reported no remaining Revolution Medicines position as of Q4 2021 after selling out during the quarter.
Wilbanks Smith & Thomas Asset Management sold 9,041 Revolution Medicines shares in Q4 2021, an estimated $249K.
Wilbanks Smith & Thomas Asset Management first reported a position in Revolution Medicines in Q4 2020 and held it in 4 quarters.
Wilbanks Smith & Thomas Asset Management's Revolution Medicines position peaked at $415K in Q1 2021.
117 funds tracked by Wall St. Rank held Revolution Medicines as of Q4 2021.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2021, filed 8 Feb 2022.